Last Updated : June 9, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
|Brand Name||Generic Name||Therapeutic Area||Recommendation Type Sort descending||Project Status||Date Submission Received||Date Recommendation Issued|
|TBC||etonogestrel||Prevention of pregnancy||Withdrawn|
|Keytruda and Lenvima||pembrolizumab and lenvatinib||Advanced endometrial cancer||Withdrawn|
|Tysabri||natalizumab||Multiple Sclerosis, relapsing-remitting||Withdrawn|
|Breo Ellipta||fluticasone furoate/vilanterol||Asthma||Withdrawn|